Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions

Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas

(2017) Gaetane Nocturne et al.   JOURNAL OF AUTOIMMUNITY

Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions

(2017) Gregory S. Calip et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers

(2016) Karin Hellgren et al.   ANNALS OF THE RHEUMATIC DISEASES

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

(2016) Louise K Mercer et al.   ANNALS OF THE RHEUMATIC DISEASES

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

(2015) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

The Quasi-cohort Approach in Pharmacoepidemiology

(2015) Samy Suissa   EPIDEMIOLOGY

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

(2015) Jasvinder A. Singh et al.   ARTHRITIS CARE & RESEARCH

Biosimilars: The Need, The Challenge, The Future: The FDA Perspective

(2014) Michael S Epstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

AB0376 Neither RA Disease Activity nor TNFI Increase the Incidence of Lymphoma in A Large, US RA Registry: Table 1.

(2014) D.E. Furst et al.   ANNALS OF THE RHEUMATIC DISEASES

Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature

(2014) Sara Monti et al.   CLINICAL RHEUMATOLOGY

Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma

(2014) Wendy J. Langeberg et al.   SUPPORTIVE CARE IN CANCER

Ankylosing Spondylitis, Psoriatic Arthritis, and Risk of Malignant Lymphoma: A Cohort Study Based on Nationwide Prospectively Recorded Data From Sweden

(2014) K. Hellgren et al.   Arthritis & Rheumatology

Risk of Lymphoma in Patients With Ulcerative Colitis Treated With Thiopurines: A Nationwide Retrospective Cohort Study

(2013) Nabeel Khan et al.   GASTROENTEROLOGY

Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs

(2013) Daniel H. Solomon et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data

(2013) Cecilia P. Chung et al.   VACCINE

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study

(2012) Michael E. Weinblatt et al.   ARTHRITIS AND RHEUMATISM

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial

(2012) Ronald F van Vollenhoven et al.   LANCET

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessing the safety of biologic agents in patients with rheumatoid arthritis

(2012) A. Rubbert-Roth   RHEUMATOLOGY

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

(2011) X. Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: A review of their methodologies and results

(2011) D. H. Solomon et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians

(2011) William H. Shrank et al.   JOURNAL OF GENERAL INTERNAL MEDICINE

Ten years with biologics: to whom do data on effectiveness and safety apply?

(2010) J. F. Simard et al.   RHEUMATOLOGY

A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries

(2010) Jeffrey R. Curtis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Comparison of Anti-TNF Treatment Initiation in Rheumatoid Arthritis Databases Demonstrates Wide Country Variability in Patient Parameters at Initiation of Anti-TNF Therapy

(2010) Chris Pease et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Tumor necrosis factor and cancer, buddies or foes?

(2009) Xia Wang et al.   ACTA PHARMACOLOGICA SINICA

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

(2009) X Mariette et al.   ANNALS OF THE RHEUMATIC DISEASES

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?

(2009) Johan Askling et al.   ARTHRITIS AND RHEUMATISM

Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry

(2009) Francesca Bobbio Pallavicini et al.   AUTOIMMUNITY REVIEWS

Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study

(2009) S. J. LEE et al.   JOURNAL OF RHEUMATOLOGY

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

(2008) J Askling et al.   ANNALS OF THE RHEUMATIC DISEASES